Loading organizations...
§ Private Profile · Lausanne, Vaud, Switzerland
Medtech company developing an active implantable neurostimulator for erectile dysfunction, focused on men unresponsive to oral drugs.
Founded in 2017 by Rodrigo Fraga-Silva, Nikos Stergiopoulos, and Mikael Sturny, Comphya is a medical technology company based in Lausanne developing CaverSTIM, an active implantable neurostimulator. This device treats erectile dysfunction in men who are unresponsive to oral drugs, specifically targeting patients with disrupted neural pathways from spinal cord injuries or prostatectomies. Operating as an EPFL spinoff, the enterprise has raised three million US dollars in seed funding and an oversubscribed Series A round of seven and a half million Swiss francs. The startup is backed by venture capital investors including Investiere, Zurich Cantonal Bank, and the NEST pension fund, with Steve Swinson serving as Chairman of the board. Following strong pilot data, the firm is currently advancing its clinical programs across the United States and Australia while actively preparing for an upcoming Series B financing round.
Comphya has raised $14.6M across 4 funding rounds.
Comphya has raised $14.6M in total across 4 funding rounds.
Comphya has raised $14.6M across 4 funding rounds. Most recently, it raised $9.3M Series A in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 8, 2025 | $9.3M Series A | — | — | Announced |
| Jan 31, 2023 | $920K Venture Round | — | Praxis Spinal Cord Institute | Announced |
| Dec 1, 2020 | $1.4M Venture Round | Foundation For Technological Innovation | — | Announced |
| May 3, 2019 | $3M Seed | Susanne Schorsch | Nest%20pension%20fund, Z%C3%BCrcher%20Kantonalbank | Announced |
Comphya has raised $14.6M in total across 4 funding rounds.
Comphya's investors include Praxis Spinal Cord Institute, Foundation for Technological Innovation, Susanne Schorsch, NEST%20pension%20fund, Z%C3%BCrcher%20Kantonalbank.